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Dear Editor,  
During the H1N1 viral respiratory epidemic some patients required admission to the Intensive care 
unit (ICU) and ECMO was sometimes used after failure of mechanical ventilation (1,2). Infectious 
complications of ECMO are ranked second after haemorragic complications, and are mainly 
represented by bloodstream infections (BSI) with Gram-positive cocci (3,4). We report the main 
clinical and microbiological findings of 16 patients (Table 1) with H1N1-ARDS treated with or 
without ECMO, according to the Italian guidelines (2,5).  
All patients were treated with empiric antibiotic treatment and oseltamivir. ECMO was used for 
15.14 + 14.01days (range, 7-46) after a mean of 1.9 days of mechanical ventilation. Respiratory 
samples were positive during the ICU stay in seven patients: five (71.4%) in ECMO group (multi-
drug resistant (MDR) P. aeruginosa, MDR S. maltophilia, S. marcescens, MDR A. baumannii, K. 
pneumoniae producing carbapenemases (KPC) and Aspergillus fumigatus) compared to two 
(22.2%) in the no-ECMO group (two A. baumanni isolates) (p =0.04). There was only one positive 
blood culture for S. marcescens in the ECMO group. The mortality was 28.6% and 44.4% in 
patients treated with or without ECMO, respectively. An infection was the probable cause of death 
in all patients who died. A possible fungal infection by A. fumigatus was responsible for one death. 
Selective antibiotic pressure …… We investigated the possible role of selective antibiotic pressure 
as a predisposing factor for the isolation of respiratory MDR Gram-negative bacteria. The mean 
daily defined doses (DDDs) at 14 days were 347 Vs. 1020 (p=0.04) for meropenem and 316 Vs. 
632 (p=0.012) for levofloxacin in the ECMO Vs. no-ECMO group, respectively. By converse, 
vancomycin and linezolid DDDs were higher in the ECMO group compared to the no-ECMO 
group: 138 Vs. 102 and 561 Vs. 122, respectively (not significant).  
The rate of infections during ECMO varies from 7.5% to 45.5% and are more often caused by MDR 
bacteria isolated from the bloodstream (4,5). In our ECMO patients the isolation of respiratory 
MDR Gram-negative bacteria may be due to the specific setting of H1N1 syndrome probably 
favoured by the mechanical ventilation, the comorbidities but not by a significantly higher antibiotic 
consumption against Gram-negatives. In conclusion, notwithstanding the low number of H1N1 
patients, we found that in ECMO patients there is a significantly higher rate of respiratory MDR 
Gram-negative bacteria which is not explained by an excessive selective antibiotic pressure, 
suggesting that H1N1 infection and ICU stay are more important as risk factors compared to the 
ECMO support itself. 
 
 
 
  
 
 
Table 1.  Demographics and clinical characteristics of patients treated without or with ECMO. 
        
Variable NO ECMO (n=9) ECMO (n=7) 
Age, mean (SD) 58 + 15.6 35.5  + 11.1 
Male sex, n (%) 3 (33.3) 5 (71.4) 
BMI, n (%) 
≥40 
30-39 
 
0 
3 (33.3) 
 
2 (28.6) 
5 (71.4) 
Comorbidities, n (%) 
- Asthma 
- COPD 
- Cardiovascular diseases 
- Chronic Renal Failure (CRF) 
- Diabetes 
- Haematologic disease 
- Solid organ cancer 
 
7 (77.8) 
2 (22.2) 
1 (11) 
3 (33.3) 
0 
2 (22.2) 
4 (44.4) 
1 (11) 
 
 
2 (28.6) 
1 (14.3) 
0 
0 
1 (14.3) 
0 
1 (14.3) 
1 (14.3) 
 
APACHE II Score, mean (SD) 21.3 +4.5 14.8+ 7 
P/F on ICU admission, mean (+SD) 89 + 42.8 73 ± 24.1 
Mortality, n (%) 4 (44.4) 2 (28.6) 
Duration of hospital stay (days) 
ICU 
Total 
ECMO support 
 
14.5 (1-44) 
19.6 (6-49) 
- 
 
28.2 (9-63) 
31.57 (18-66) 
15.1 (7-46) 
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